{"paper_id":"1bceee33-6103-4b1a-a588-162fb5de07b2","body_text":"References\nJeon J, Kim SE, Lee DY et al (2020) Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat 179:125–130\nFisher B, Costantino JP, Redmond CK et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537\nNeven P, De Muylder X, Van Belle Y et al (1989) Tamoxifen and the uterus and endometrium. Lancet 8634:375\nDal Cin P, Timmerman D, Van den Berghe I et al (1998) Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 58:2278–2281\nNeven P, Vergote I (1988) Should tamoxifen users be screened for endometrial lesions? Lancet 351:155–157\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of interest\nThe authors declare that they have no conflict of interest.\nEthical approval\nThis article does not contain any studies with human participants performed by any of the authors.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nNeven, P., Froyman, W., Timmerman, S. et al. Uterine ultrasound and endometrial biopsy in tamoxifen users. Breast Cancer Res Treat 180, 833–834 (2020). https://doi.org/10.1007/s10549-020-05595-5\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s10549-020-05595-5","source_license":"CC0","license_restricted":false}